Certolizumab pegol in treatment of psoriasis and psoriatic arthritis: patient profiles, inspection, monitoring of safety
https://doi.org/10.33667/2078-5631-2021-9-79-82
About the Authors
A. A. Khotko
Clinical Dermatovenerologic Dispensary, Krasnodar
Russian Federation
Russian Federation
Hotko Alkes A., PhD Med, deputy chief physician
M. Yu. Pomazanova
Clinical Dermatovenerologic Dispensary, Krasnodar
Russian Federation
Russian Federation
Pomazanova Marina Yu.,head of Inpatient Dept
Ya. V. Kozyr
Kuban State Medical University, Krasnodar
Russian Federation
Russian Federation
Kozyr Yana V.,clinical resident
References
1. Russian Society of Dermatovenereologists and Cosmetologists. Clinical guidelines. Psoriasis. http://cr.rosminzdrav.ru/#!/recomend/866.
2. Bakulev A. L., Fitileva T. V., Novoderezhkina E. A., Gillotyu I., Tian H., Hove T., Petri G. Psoriasis: clinical and epidemiological features and issues of therapy. Results of a survey of patients and doctors conducted in medical organizations in Russia. Bulletin of Dermatology and Venereology. 2018.94, No. 3. P. 67–76.
3. Osina A. V., Ponich E. S., Kruglova L. S. Psoriasis and Cancer: Potential Relationships and Potential Risks. Russian Journal of Skin and Venereal Diseases. 2017. No. 5.
4. Azfar R. S., Gelfand J. M. Psoriasis and metabolic diseases: Epidemiology and pathophysiologyю Curr Opin Rheumatol. 2008; 20 (4): 416–422.
5. Kurizky P. S., Ferreira C de C., Nogueira L. S.C., da Mota L. M.H. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding. An. Bras. Dermatol. 2015; 90: 367–375.
6. Trushina L. S., Agababoka E. R. and other Clinical variants and morphological picture of articular syndrome in patients with psoriasis. Ter. Arch. 1983. No. 2. P. 123–126.
7. Olisova O. Yu., Garanyan L. G. Comorbidity in psoriasis. Russian Journal of Skin and Venereal Diseases. 2016. No. 6.
8. Okorokov A. N. Diagnostics of diseases of internal organs. In 10 volumes. T.
9. Koleva N. N. Arthropathic psoriasis. DVKS. 2010. URL: https://cyberleninka.ru/article/n/artropaticheskiy-psoriaz (date of access: 24.02.2021).
10. Nesbitt et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents. Infl Bowel Dis. 2007; 13 (11): 1323–1332.
11. Clinical Immunology: Lead. for doctors. Ed. E. I. Sokolov. M.: Medicine, 1996. 272 p.
12. Milevskaya S. G., Bazhenova O. B. The level of immunoglobulins in psoriatic arthritis, psoriasis and rheumatoid arthritis. GRM. 1985. No. 7. P. 11.
13. Sokolovsky E. V., Kruglova L. S., Ponich E. S. ‘Painful’ points of systemic therapy with biological agents in psoriasis. Russian Journal of Skin and Venereal Diseases. 2015. No. 6.
14. Carron P. et al. Scintigraphic Detection of TNFα with a Radiolabeled Anti-TNFα in Patients with Active Peripheral Spondyloarthritis and Rheumatoid Arthritis. Arthritis and Rheumatism. 2016. 65, 10. e000265.
15. Cassinotti A., Ardizzone S., Porro G B. Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn’s disease. Core Evid. 2008; 2 (3): 209–229.
16. Campanati A, Benfaremo D, Luchetti MM, Ganzetti G, Gabrielli A, Offidani A. Certolizumab pegol for the treatment of psoriasis. Expert Opin Biol Ther. 2017 Mar; 17 (3): 387–394. DOI: 10.1080/14712598.2017.1283401. Epub 2017 Feb 6. PMID: 28165828.
17. Tracey et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacology & Therapeutics 2008; 117 (2): 244–279.
18. Mariette X., Förger F., Abraham B. et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018; 77 (2): 228–233. DOI: 10.1136/annrheumdis-2017–212196
Review
For citations:
Khotko A.A., Pomazanova M.Yu., Kozyr Ya.V. Certolizumab pegol in treatment of psoriasis and psoriatic arthritis: patient profiles, inspection, monitoring of safety. Medical alphabet. 2021;(9):79-82. (In Russ.) https://doi.org/10.33667/2078-5631-2021-9-79-82
Views:
370
Email this article 